| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Lymphoma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Lymphoma, B-Cell | |||||
| Lymphoma, Non-Hodgkin | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 4 | Interventions listed in this trial | ||||
| recombinant interleukin-12 | |||||
| rituximab | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Interleukin-12 | |||||
| 6 | More general drug interventions related to this trial | ||||
| Adjuvants, Immunologic | |||||
| Angiogenesis Inhibitors | |||||
| Angiogenesis Modulating Agents | |||||
| Antineoplastic Agents | |||||
| Antirheumatic Agents | |||||
| Growth Inhibitors | |||||
| Growth Substances | |||||
| Immunologic Factors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| North Central Cancer Treatment Group | |||||
| National Cancer Institute (NCI) | |||||
|
